Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0GQCHO)
| ADC Name |
HMBD-802
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
HMBD-802; CLIO-8221
Click to Show/Hide
|
|||||
| Organization |
Hummingbird Bioscience (Originator);Callio Therapeutics
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
4+4
|
|||||
| Antibody Name |
Anti-HER2 mAb
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
Exatecan; ATR inhibitor
|
Payload Info | ||||
| Payload Target |
ATR+DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC